ExonHit licenses Merck rights to RNA splicing microarray patent

Download PDF Copy

Editorial Checklist

Reviewed

Sep 11 2006

NewsGuard 100/100 Score

ExonHit Therapeutics S.A., a drug and diagnostic discovery company, has announced that Merck & Co., Inc. has been granted a non-exclusive license to rights for research only under Patent US 6,881,571.

It is not anticipated that the revenues received by ExonHit from Merck under this agreement will exceed US$150,000 per year.

Patent US 6,881,571, entitled "Qualitative Differential Screening", was granted on April 19, 2005 and has claims directed to microarrays optimized for the monitoring of RNA splicing events.

Source:

http://www.exonhit.com

Posted in: Medical Patent News

Tags: Diagnostic, Microarray, Research, RNA, Splicing, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Spatial transcriptomics uncovers tissue niches in multiple sclerosis

Spatial transcriptomics uncovers tissue niches in multiple sclerosis

Memories of obesity can linger in fat cells long after weight loss

Memories of obesity can linger in fat cells long after weight loss

The crucial role of sleep in heart healing

The crucial role of sleep in heart healing

Squid-inspired technology could replace needles for medications and vaccines

Squid-inspired technology could replace needles for medications and vaccines

Innovative urine test could improve pancreatic cancer survival rates

Innovative urine test could improve pancreatic cancer survival rates

How gut bacteria regulate stress and sleep cycles

How gut bacteria regulate stress and sleep cycles

New insights into early Huntington's disease mechanisms

New insights into early Huntington's disease mechanisms

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Exploring the G:Box and for high-quality imaging